2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| 4.79 | |
| 4.69 | |
| - | |
| 4.825 | |
| 4.53 | |
| 1.535-8.08 | |
| 235 M | |
| 51 405 K | |
| 71 201 K | |
| -1.01 | |
| 1.77 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made. But finding these stocks can be a challenge. Having access to information investo...
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
